LigaChem Biosciences

At a glance

LigaChem Biosciences filed 49 disclosures in the last 12 months, including 6 5% holder, 3 insider and 2 issuance. The most recent key filing was on Oct 2.

Revenue for 2025 was ₩142B, up 12.4% on 2024. It made an operating loss of ₩106B. Debt was 30% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩41.4B and operating loss of ₩109B.

The 2025 annual report lists 180 employees with an average tenure of 4.8 years and average pay of ₩157.1M, #25 of 1,829 listed companies by average pay. Its 8 directors and auditors were paid ₩138M each on average. It paid no cash dividend for 2025. PAN ORION Corp. Limited and related parties held 29.60% at year end.

From the 2025 annual report

Staff: 180 (84 men, 96 women), of whom 9 on fixed-term contracts. Total pay for the year: ₩28.2B. Directors and auditors: 8, paid ₩1.1B in total.

No cash dividend was paid for 2025.

Largest shareholder

PAN ORION Corp. Limited holds 25.58%; with 9 related parties the group holds 29.60% of common shares at year end (from 29.62% at the start of the year).

Individuals paid ₩500M or more

Auditor: 삼정회계법인 · opinion: Unqualified.

Rankings: Average pay #25 of 1,829

Source: 2025 annual business report (DART). How figures are combined

Financial summary